The FDA granted Breakthrough Therapy status to zovegalisib plus Faslodex for patients with PIK3CA-mutated HR+/HER2- advanced breast cancer. The U.S. Food and Drug Administration (FDA) has granted ...
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results